Compare PLSE & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSE | QURE |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.1B |
| IPO Year | 2015 | 2013 |
| Metric | PLSE | QURE |
|---|---|---|
| Price | $51.63 | $37.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 14 |
| Target Price | $22.00 | ★ $45.00 |
| AVG Volume (30 Days) | 612.2K | ★ 1.2M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | $840.00 | $126.12 |
| Revenue Next Year | $287.54 | $200.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.56 | $8.73 |
| 52 Week High | $58.90 | $71.50 |
| Indicator | PLSE | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 54.39 | 30.65 |
| Support Level | $49.01 | $35.34 |
| Resistance Level | $58.90 | $51.09 |
| Average True Range (ATR) | 4.59 | 2.07 |
| MACD | -0.70 | -0.78 |
| Stochastic Oscillator | 35.18 | 11.91 |
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.